Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Lancet Neurology

• Publication date

  2025-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1474-4422(25)00174-7PMID 40683275
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.

  2025cited by this paper
• Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

  2024cited by this paper
• Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis

  2024cited by this paper
• BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair

  2024cited by this paper
• Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis

  2024cited by this paper
• Bruton tyrosine kinase inhibitors for multiple sclerosis

  2023cited by this paper
• Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis

  2023cited by this paper
• Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis

  2022cited by this paper
• Multiple sclerosis progression: time for a new mechanism-driven framework.

  2022cited by this paper
• BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy

  2022cited by this paper
• Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

  2021cited by this paper
• Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances.

  2021cited by this paper
• Paramagnetic Rim Sign in Radiologically Isolated Syndrome.

  2020cited by this paper
• Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

  2019cited by this paper
• Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

  2018cited by this paper
• Multiple Sclerosis

  2018cited by this paper
• Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor

  2018cited by this paper
• Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

  2018cited by this paper
• Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

  2017cited by this paper
• Optimizing treatment success in multiple sclerosis

  2015cited by this paper
• Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

  2014cited by this paper
• Temporally Consistent Probabilistic Detection of New Multiple Sclerosis Lesions in Brain MRI

  2013cited by this paper
• Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

  2011cited by this paper
• Idiosyncratic toxicity: a convergence of risk factors.

  2007cited by this paper
• Role of Bruton's Tyrosine Kinase in B Cell Development

  2001cited by this paper

• Targeting of Kinases to Treat Neurodegenerative Diseases

  2026cites this paper
• BTK inhibitors in multiple sclerosis: emerging evidence and future directions.

  2026cites this paper
• Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies.

  2026cites this paper
• Bruton’s Tyrosine Kinase Inhibitors and Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Review of Complementary Paradigms for a Divergent Disease

  2026cites this paper
• CAR T-Cell Immunotherapy in Neuroautoimmune Diseases: Focus on the Central Nervous System.

  2026cites this paper
• Updates on the Acute and Maintenance Management of Optic Neuritis including multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody disease

  2026cites this paper
• Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions

  2025cites this paper
• Bruton's tyrosine kinase inhibitors for multiple sclerosis.

  2025cites this paper